康莱特联合GP方案治疗晚期非小细胞肺癌疗效的系统评价

A systematic review of Kanglaite plus GP regimen in treating advanced non- small cell lung cancer

目的:观察康莱特注射液联合GP方案治疗晚期非小细胞肺癌(NSCLC)的有效性与安全性。方法:检索Cochrane图书馆临床对照试验库和CENTRAL管理资料库、Pubmed、Embase、Cancerlit、中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)、万方数据库以及重庆维普信息数据库(VIP)等电子数据库,并以手工检索和附加检索加以辅助。纳入康莱特注射液联合GP方案治疗非小细胞肺癌相关随机/半随机对照试验。使用Cochrane系统评价方法学数据库推荐的方法进行文献质量评价,并用Rev Man5.2软件进行统计分析。结果:共纳入11篇研究,11项研究合并结果均显示康莱特联合GP方案(吉西他滨+顺铂)化疗疗效优于单独化疗(RR合并=1.47,95%CI:1.22-1.78)。11篇单个研究结果均表明联合使用GP+康莱特可能减少由常规GP治疗引起的毒副反应。6篇研究显示康莱特联合GP方案化疗可明显改善或稳定化疗患者的生活质量(P<0.05)。结论:康莱特联合GP方案化疗治疗非小细胞肺癌,在一定程度上可增强常规GP方案治疗的临床疗效,减少常规GP方案引起的毒副反应,稳定并改善患者的生活质量。

Objective： Reviewing the efectiveness and safety of Kanglaite plus GP regimen for treating advanced non- small cell lung cancer（ NSCLC）. Methods： Searched the Cochrane Controlled Trials Register / CENTRAL,Pubmed,Embase,Cancerlit,CBM,CNKI,Wan Fang Data and VIP. All randomized controlled trials / quasi- RCT about Kanglaite with GP regimen on treating NSCLC were selected. Using the evaluation method which recommended by Cochrane Review Methodology Database to evaluate the quality of these medical literarure and Rev Man5. 2 software to analyse data. Results： All 11 reports were selected into the Meta- analysis. All the 11 studies indicated that the effect of Kanglaite plus GP（ Gemcitabine ＋ Cisplatin） was better than GP regimen alone（ RR = 1. 47,95% Confidence Interval： 1. 22- 1. 78）. Kanglaite plus GP may reduce the side- effect induced by regular GP regimen. 6 studies showed GP regimen plus Kanglaite can stabilite / improve quality of the patients＇ life（ P〈0. 05）. Conclusion： Kanglaite can enhance clinical effect of regular GP regimen,reduce side- effect and stabilite / improve patients＇ quality of life.